UK-based pharma decision support consultancy J&D Associates has partnered with GfK’s oncology subsidiary GfK Research Matters to market the former’s EQM platform for use with the latter’s tracking data.
J&D Research was founded in London in 2005, to help clients pinpoint market opportunities using a combination of applied market research techniques and decision support analytics. Its EQM software platform provides clients with an interactive model to view the market landscape and patient flow of different cancer indications. It allows tracking data to be used for new applications such as market forecasting, scenario planning, and market modeling covering market size, structure and influences between key players.
Chris Krattiger, MD of GfK Research Matters – which became
wholly owned by GfK in April – said that the association would enable his firm to offer clients forecasting capabilities to obtain sensitivity analysis, and more accurate quantification of their markets.
J&D Associates’ MD, David James, who developed the platform with his team of specialists, added: ‘This agreement combines the industry best forecasting platform with world-class cancer tracking data which will take clients much further in their understanding of current and future markets.
The EQM Oncology Software Platform will be available for the US, the main five EU markets including the UK, Germany, France, Italy and Spain and for some of the indications also for China and Japan. Under the agreement, the first platforms, including GfK Research Matters’ cancer data, will be available in January 2009, with subsequent markets planned for delivery during the first half of next year.
In the summer, the firm expanded
with the opening of new offices in Boston, Massachusetts. Web sites: www.janddassociates.com